10x Genomics (TXG)
Builds Chromium, Visium, Xenium, and Atera platforms for single-cell and spatial biology.
Something off on this page? Send us feedback.
Supplies instruments, consumables, and software for single-cell and spatial biology across Chromium, Visium, Xenium, and the emerging Atera platform. Revenue comes mainly from instruments and recurring consumables, which generally work only with its systems, while academic and government labs form the largest share of direct sales.
Builds instruments, consumables, and software that let researchers analyze biology at single-cell and spatial resolution. Chromium partitions and barcodes cells for sequencing-based multiomic studies; QuantumScale kits add combinatorial-indexing workflows. Visium maps whole-transcriptome expression across tissue, Xenium images targeted RNA in intact tissue, and the newly introduced Atera platform targets whole-transcriptome in situ analysis.
Sells globally to academic, government, biopharmaceutical, and biotechnology labs, using direct teams in North America and parts of Europe and distributors elsewhere. Combining chemistry, microfluidics, hardware, and analysis software supports integrated workflows.
Revenue comes primarily from instrument and consumable shipments, with extended-warranty services a small component. Consumables generally work only with its instruments, while Chromium and Visium workflows rely on third-party sequencers; academic and government institutions form the largest portion of direct sales and tie demand to research funding.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Reiterate | Rating: —Target: $20 | Target: $68 |
| Sep 1, 2026 | RBC Capital | Initiate | Rating: —Target: — | Target: $70 |
| Aug 12, 2026 | Stephens | Reiterate | Rating: —Target: — | Target: $65 |
| Aug 10, 2026 | Piper Sandler | Reiterate | Rating: —Target: — | Target: $47 |
| Aug 10, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $50 | Target: $60 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $552.0M · Total debt $78.8M · Total assets $1.03B · Shareholders' equity $825.5M
- Revenue
- $151.0M
- Operating income
- −$19.6M
- Net income
- −$17.9M
No dividends on record.
| Institutions | 101.43% | 129.58M shares | |
|---|---|---|---|
| 403 holders · as of Jun 30, 2026 | |||
| Insiders | 1.25% | 1.59M shares | |
| 9 holders · as of Sep 11, 2026 | |||
| Adds to | 102.68% | ||
127.75M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 102.68%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 13.80% | 17.63M A | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.46% | 10.80M A | as of Jun 30, 2026 |
Ark Investment Management LLCInstitution | 7.83% | 10.00M A | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.47% | 6.98M A | as of Jun 30, 2026 |
Quantinno Capital Management LPInstitution | 4.28% | 5.47M A | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 9, 2026 | Adam Taich | officer: Chief Financial Officer | −46,388 | $64.57 |
| Sep 3, 2026 | John R. Stuelpnagel | director | −20,000 | $61.75 |
| Aug 26, 2026 | Serge Saxonov | director, officer: Chief Executive Officer | −10,486 | $63.69 |
| Aug 24, 2026 | Adam Taich | officer: Chief Financial Officer | −17,166 | $63.02 |
| Aug 24, 2026 | Serge Saxonov | director, officer: Chief Executive Officer | −18,545 | $63.02 |
- Illumina
Dominant NGS sequencer now entering spatial and single-cell sample prep
- Bruker
Holds GeoMx and CosMx spatial platforms acquired from NanoString in 2024
- Waters
BD Rhapsody microwell single-cell platform, now under Waters (Feb 2026)
- Bio-Rad Laboratories
Droplet microfluidics IP holder; ddSEQ single-cell and ddPCR rival
- Standard BioTools
Mass cytometry and imaging mass cytometry tools for high-plex phenotyping
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| 10x Genomics | $80.69 | +2.02% | $10.04B | — | — | 16.3 | −12.7% |
| Illumina | $246.76 | +3.33% | $36.13B | 44.6 | 43.2 | 8.0 | +9.4% |
| Bruker | $61.36 | −0.36% | $9.37B | — | 27.1 | 2.7 | +5.2% |
| Waters | $425.35 | +0.34% | $41.62B | 105.7 | 27.2 | 9.0 | +113.3% |
| Bio-Rad Laboratories | $381.57 | +1.12% | $10.16B | 45.7 | 37.0 | 3.9 | −0.1% |
| Standard BioTools | $0.7504 | +1.15% | $290.4M | — | — | 3.4 | −7.6% |
| Median | 45.7 | 32.1 | 3.9 | +5.2% |